Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
Recruiting
Phase 1
Phase 2
Interventional Study
Solid Tumor
Colorectal Cancer (CRC)
Squamous Cell Carcinoma of Head and Neck
Non-Small Cell Lung Cancer (NSCLC)
Gastrooesophageal Junction Cancer
Gastric Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 43 (estimated)
- Sponsor
- One-carbon Therapeutics AB · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a first in human, multi-center, open-label, dosage escalation study to determine the recommended dose range of TH9619 in subjects with advanced cancer.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Must have given written informed consent
* Histopathologically confirmed advanced cancer (colorectal cancer, head and neck squamous cell cancer, non-small cell lung cancer and gastric cancer (including gastroesophageal junction cancer))
* Prior treatment with at least one line…
Contacts